Hywel Williams | Genomic Medicine | Best Researcher Award

Dr. Hywel Williams | Genomic Medicine | Best Researcher Award

Senior Lecturer | Cardiff University | United Kingdom

Dr. Hywel J. Williams is a distinguished academic and researcher currently serving as a Senior Lecturer in Bioinformatics: Genetic and Genomic Medicine in the Division of Cancer and Genetics, School of Medicine, Cardiff University, since 2019. He holds a Ph.D. in Genetics from Cardiff University (2001–2005), where his research focused on identifying schizophrenia susceptibility genes on chromosome 22 under the supervision of Prof. Sir Michael J. Owen. His earlier academic qualifications include a B.Sc. (Hons) in Genetics from Cardiff University (1994–1996) and an HND in Applied Biology from the University of Wales Institute Cardiff (1992–1994). Dr. Williams also earned recognition as an Associate Fellow of the Higher Education Academy in 2018. With over two decades of research experience, his career spans roles such as Senior Research Associate at UCL’s Great Ormond Street Institute of Child Health (2013–2018), and various research positions at Cardiff University from 1997 to 2012. His work integrates bioinformatics, genomics, and molecular genetics, with a primary focus on rare diseases, psychiatric genetics, and genomic medicine. His key contributions include joint first authorship of the landmark study “The 100,000 Genomes Pilot on Rare Disease Diagnosis in Healthcare” published in the New England Journal of Medicine (2021), and senior authorship in studies enhancing rapid pediatric sequencing and understanding of genetic disorders. Dr. Williams possesses advanced research skills in genomic data analysis, variant interpretation, computational biology, and multi-omic integration, contributing to the clinical translation of genome sequencing technologies. With an outstanding academic record—over 19,000 citations, an h-index of 56, and an i10-index of 101—he is recognized for his influential work in genomic research and data-driven healthcare. His career reflects a commitment to improving diagnostic accuracy and patient care through innovative bioinformatics approaches, making him a key contributor to the global advancement of precision and personalized medicine.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

  1. Purcell, S. M., Wray, N. R., Stone, J. L., Visscher, P. M., O’Donovan, M. C., Sullivan, P. F., Williams, H. J., et al. (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature, 460(7256), 748–752. https://doi.org/10.1038/nature08185 Cited by: 5,521

  2. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2011). Genome-wide association study identifies five new schizophrenia loci. Nature Genetics, 43(10), 969–976. https://doi.org/10.1038/ng.940 Cited by: 2,110

  3. Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., et al. (2014). De novo mutations in schizophrenia implicate synaptic networks. Nature, 506(7487), 179–184. https://doi.org/10.1038/nature12929 Cited by: 1,920

  4. O’Donovan, M. C., Craddock, N., Norton, N., Williams, H., Peirce, T., Moskvina, V., et al. (2008). Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genetics, 40(9), 1053–1055. https://doi.org/10.1038/ng.201 Cited by: 1,327

  5. 100,000 Genomes Project Pilot Investigators (including Williams, H. J.). (2021). 100,000 genomes pilot on rare-disease diagnosis in health care—preliminary report. New England Journal of Medicine, 385(20), 1868–1880. https://doi.org/10.1056/NEJMoa2035790 Cited by: 657

Gareth Baynam | Genetics | Best Researcher Award

Prof. Dr. Gareth Baynam | Genetics | Best Researcher Award

Medical Director  at The Rare Care Centre, Perth Children’s Hospital, Australia

Clinical Professor Gareth Baynam is a globally recognized leader in rare diseases, precision public health, and equitable healthcare innovation. With over two decades of experience as a clinical geneticist and translational scientist, he holds numerous influential roles across academia, healthcare policy, and genomics research, including Director of the Undiagnosed Diseases Network International and Medical Director of the Rare Care Centre in Western Australia. His work focuses on advancing health equity, particularly for children, Indigenous populations, and those with rare diseases. Gareth has pioneered several international collaborations and state-wide initiatives, transforming research into sustainable clinical applications. His influential publications and numerous accolades, including the Western Australia Minister for Health’s Award and recognition from the Genetic and Rare Diseases Network, underscore his profound impact on healthcare systems and patient communities. His innovative, inclusive, and patient-centered approach makes him a strong and highly suitable candidate for the Best Researcher Award.

Professional Profile 

Education🎓

Professor Gareth Baynam possesses an impressive and multidisciplinary educational background that underpins his impactful career in clinical genetics and public health innovation. He obtained his Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Western Australia in 1997, followed by a Diploma in Child Health (DCH) in 1999. He earned his Fellowship from the Royal Australasian College of Physicians (FRACP) in 2001, specializing in Medicine. Driven by a passion for translational research, he completed a Ph.D. in Vaccine Genetics at the University of Western Australia in 2008, further strengthening his foundation in genomic science. In 2020, he also became an Associate Fellow of the Australasian Institute of Digital Health (A/FAIDH), reflecting his commitment to health informatics and digital health transformation. His comprehensive education equips him with the clinical, scientific, and technological expertise necessary to lead innovative healthcare initiatives and influence global health policies, particularly in rare disease research and precision medicine.

Professional Experience📝

Professor Gareth Baynam has a distinguished professional career that spans clinical practice, academic leadership, health policy, and global research collaboration. Since 2008, he has served as a Clinical Geneticist at Genetic Services of Western Australia, where he provides expert care and contributes to advancing genetic medicine. He held the position of Raine Clinician Research Fellow from 2014 to 2019, a prestigious role that allowed him to bridge clinical service with impactful research. He has served as a Clinical Associate Professor and later Clinical Professor at the University of Western Australia, and also holds academic appointments at Curtin University, the University of Notre Dame, and serves on multiple national and international advisory boards. As Medical Director of the Rare Care Centre and Director of the Undiagnosed Diseases Network International, he leads innovative initiatives in rare disease diagnosis and care. His professional journey is marked by a deep commitment to equitable healthcare and translational genomics.

Research Interest🔎

Professor Gareth Baynam’s research interests lie at the intersection of clinical genetics, precision public health, and equitable healthcare delivery. He is particularly passionate about improving outcomes for individuals with rare diseases, birth defects, and cerebral palsy, with a strong focus on Indigenous and underserved communities. His work emphasizes the use of innovative technologies—ranging from ancient knowledge systems to modern genomics and digital health—to develop sustainable, patient-centered healthcare solutions. He is a pioneer in translational science, transforming cutting-edge research into real-world clinical applications through deep community engagement and multi-sector partnerships. Professor Baynam also plays a critical role in shaping health policy and genomic strategies at national and global levels. His efforts support the integration of precision medicine into primary care systems and promote health equity through public-private partnerships. Ultimately, his research is driven by a commitment to ensuring that scientific advances reach those most in need, creating a global impact in rare disease care.

Award and Honor🏆

Professor Gareth Baynam has received numerous prestigious awards and honors in recognition of his exceptional contributions to healthcare, research, and innovation. In 2019, he was awarded the Western Australia Minister for Health’s Award—the highest accolade in the WA Health System—for his significant and sustainable impact on population-scale health innovations, particularly benefiting children, youth with rare diseases, and Aboriginal communities. In 2018, he was bestowed with the first Honorary Lifetime Membership of the Genetic and Rare Diseases Network WA (GaRDN), honoring his tireless dedication and collaborative efforts to improve the lives of those affected by genetic and rare diseases. He was also a finalist in the 2019 Premier’s Science Awards, reflecting his prominence in scientific advancement. More recently, in 2024, he was named a finalist for both the Channel 7 Child Health Hero and the NMHS NAIDOC Award, further highlighting his continued excellence in child health advocacy and Indigenous health initiatives.

Research Skill🔬

Professor Gareth Baynam possesses a comprehensive and impactful set of research skills that span clinical genetics, public health, policy development, and translational science. He excels in designing and implementing research frameworks that bridge the gap between cutting-edge science and real-world healthcare delivery, particularly in the context of rare diseases and underserved populations. His skills include leading multi-disciplinary, cross-sectoral collaborations and translating complex genomic research into accessible clinical applications. He is adept in data-driven innovation, combining modern informatics with traditional and community-based knowledge to address health disparities. Professor Baynam demonstrates exceptional ability in stakeholder engagement, having successfully coordinated national and international initiatives involving governments, NGOs, industry partners, and Indigenous communities. He also contributes to health system reforms through policy advising, guideline development, and capacity-building. His research leadership has not only advanced scientific understanding but also ensured that innovations lead to tangible, sustainable improvements in patient care and health equity globally.

Conclusion💡

Professor Gareth Baynam stands out as an exemplary candidate for the Best Researcher Award due to his:

  • Leadership in global health and rare disease research.

  • Multidisciplinary and international contributions.

  • Commitment to equitable, inclusive, and translational science.

  • Recognized excellence through prestigious awards and global collaborations.

He not only meets but exceeds the typical criteria expected for this award. With minor enhancements in showcasing commercialization potential and international collaborations (esp. with Singapore), his profile could serve as a benchmark for impactful, socially conscious scientific leadership.

Publications Top Noted✍️

  • Title: The human phenotype ontology in 2021
    Authors: S Köhler, M Gargano, N Matentzoglu, LC Carmody, D Lewis-Smith, et al.
    Year: 2021
    Citations: 901

  • Title: Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources
    Authors: S Köhler, L Carmody, N Vasilevsky, JOB Jacobsen, D Danis, JP Gourdine, et al.
    Year: 2019
    Citations: 743

  • Title: The human phenotype ontology in 2017
    Authors: S Köhler, NA Vasilevsky, M Engelstad, E Foster, J McMurry, S Aymé, et al.
    Year: 2017
    Citations: 653

  • Title: How many rare diseases are there?
    Authors: M Haendel, N Vasilevsky, D Unni, C Bologa, N Harris, H Rehm, et al.
    Year: 2020
    Citations: 464

  • Title: International cooperation to enable the diagnosis of all rare genetic diseases
    Authors: KM Boycott, A Rath, JX Chong, T Hartley, FS Alkuraya, G Baynam, et al.
    Year: 2017
    Citations: 447

  • Title: The human phenotype ontology in 2017
    Authors: S Kohler, NA Vasilevsky, M Engelstad, E Foster, J McMurry, S Ayme, et al.
    Year: 2017
    Citations: 383

  • Title: Mutations in a TGF-β Ligand, TGFB3, Cause Syndromic Aortic Aneurysms and Dissections
    Authors: AM Bertoli-Avella, E Gillis, H Morisaki, JMA Verhagen, BM De Graaf, et al.
    Year: 2015
    Citations: 341

  • Title: Modeling 3D facial shape from DNA
    Authors: P Claes, DK Liberton, K Daniels, KM Rosana, EE Quillen, LN Pearson, et al.
    Year: 2014
    Citations: 335

  • Title: X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes
    Authors: H Hu, SA Haas, J Chelly, H Van Esch, M Raynaud, APM de Brouwer, et al.
    Year: 2016
    Citations: 330

  • Title: Rights, interests and expectations: Indigenous perspectives on unrestricted access to genomic data
    Authors: M Hudson, NA Garrison, R Sterling, NR Caron, K Fox, J Yracheta, et al.
    Year: 2020
    Citations: 255

  • Title: Future of rare diseases research 2017–2027: an IRDiRC perspective
    Authors: CP Austin, CM Cutillo, LPL Lau, AH Jonker, A Rath, D Julkowska, et al.
    Year: 2017
    Citations: 255

  • Title: The human phenotype ontology: semantic unification of common and rare disease
    Authors: T Groza, S Köhler, D Moldenhauer, N Vasilevsky, G Baynam, T Zemojtel, et al.
    Year: 2015
    Citations: 240

  • Title: Extending the phenotypes associated with DICER1 mutations
    Authors: WD Foulkes, A Bahubeshi, N Hamel, B Pasini, S Asioli, G Baynam, et al.
    Year: 2011
    Citations: 215

  • Title: Mutation Update for Kabuki Syndrome Genes KMT2D and KDM6A and Further Delineation of X‐Linked Kabuki Syndrome Subtype 2
    Authors: N Bögershausen, V Gatinois, V Riehmer, H Kayserili, J Becker, et al.
    Year: 2016
    Citations: 197

Ahmet Altay | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Assoc. Prof. Dr. Ahmet Altay | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Erzincan Üniversitesi, Turkey

Dr. Ahmet Altay is an accomplished researcher and academic in the field of chemistry, specializing in biochemistry, medicinal chemistry, and interdisciplinary sciences. With a strong background in natural product chemistry and anticancer drug discovery, he has contributed significantly to the scientific community through his research on antioxidants, cytotoxic agents, and enzyme inhibition. His extensive publication record in high-impact SCI-Expanded journals highlights his expertise in experimental and computational studies. Currently serving as an Associate Professor at Erzincan Binali Yıldırım University, Dr. Altay continues to push the boundaries of chemical and biochemical research, focusing on novel therapeutic compounds and their biological applications.

Professional Profile 

Education

Dr. Ahmet Altay earned his Ph.D. in Biochemistry from Middle East Technical University (METU), Turkey, in 2015. His doctoral research focused on the antioxidant and cytotoxic properties of Salvia fruticosa M., as well as its effects on cytochrome P450 enzymes and antioxidant gene expression in colon cancer cells.

Professional Experience

Dr. Altay has been a faculty member at Erzincan Binali Yıldırım University since 2016. He started as an Assistant Professor (2016-2018), was promoted to Associate Professor in 2020, and has since been actively involved in research and teaching. His work spans multiple disciplines within chemistry and biochemistry, with a strong focus on drug discovery and molecular interactions. His contributions include supervising graduate students, securing research grants, and collaborating on international scientific projects.

Research Interests

Dr. Ahmet Altay’s research interests lie at the intersection of biochemistry, medicinal chemistry, and pharmacology, with a particular focus on drug discovery and natural product chemistry. His work extensively explores the antioxidant, anticancer, and enzyme-inhibitory properties of bioactive compounds derived from medicinal plants. He is also deeply engaged in molecular docking studies to understand drug-receptor interactions at a computational level. Additionally, his research investigates apoptosis mechanisms, oxidative stress-related disorders, and the modulation of key metabolic pathways in cancer and neurodegenerative diseases. By integrating experimental and computational approaches, Dr. Altay aims to develop novel therapeutic agents that can target cancer, microbial infections, and enzyme-related disorders. His interdisciplinary research combines chemical synthesis, molecular modeling, and pharmacological evaluation to provide innovative solutions in biomedical sciences.

Awards and Honors

Dr. Ahmet Altay has received multiple awards and recognitions for his outstanding contributions to scientific research and academia. His excellence in publishing high-impact research has been acknowledged with best paper awards and recognitions from international conferences and scientific organizations. He has been honored with research grants and funding support for his projects on natural product chemistry and drug discovery. As an active academic, he has also received accolades for his contributions to student mentorship and scientific collaboration. His efforts in cancer research and enzyme inhibition studies have been recognized by national and international institutions. Additionally, his role as a peer reviewer and editorial board member in prestigious scientific journals highlights his expertise and influence in the field. These awards and honors underscore his dedication to advancing biomedical and pharmaceutical sciences.

Research Skills

Dr. Ahmet Altay possesses a diverse set of research skills spanning experimental and computational methodologies. His expertise includes the isolation and structural characterization of bioactive natural products using advanced chromatographic and spectroscopic techniques such as HPLC, GC-MS, and NMR. He is highly proficient in molecular docking, molecular dynamics simulations, and in silico drug design to predict ligand-target interactions. His skills in biochemical assays enable the evaluation of antioxidant, antimicrobial, and anticancer activities of synthetic and natural compounds. Additionally, he has extensive experience in enzyme kinetics, apoptosis studies, and gene expression analysis using RT-PCR and Western blot techniques. His interdisciplinary knowledge allows him to integrate synthetic chemistry, pharmacology, and bioinformatics to address complex biomedical challenges. Dr. Altay’s strong analytical skills, coupled with his experience in mentoring and collaboration, make him a leading researcher in his field.

Conclusion

Dr. Ahmet Altay is a strong candidate for the Best Researcher Award due to his high research output, international collaborations, and contributions to anticancer and biochemical research. To enhance his profile further, he could focus on leading large-scale projects, securing more grants, and publishing in top-tier journals. Nonetheless, his achievements make him a compelling nominee for this award.

Publications Top Noted

  • Title: Diffractaic acid exerts anti-cancer effects on hepatocellular carcinoma HepG2 cells by inducing apoptosis and suppressing migration through targeting thioredoxin reductase 1

    • Authors: Emine Karaca Sulukoğlu, Şükran Günaydın, Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2024
    • Citation: Naunyn-Schmiedeberg’s Archives of Pharmacology
    • DOI: 10.1007/s00210-024-02980-5
  • Title: The Combined Effect of Vulpinic Acid and Doxorubicin in Breast Cancer MCF-7 Cells

    • Authors: Esma Kübra Kağan Yeniçeri, Ahmet Altay
    • Year: 2024
    • Citation: Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
    • DOI: 10.18185/erzifbed.1376859
  • Title: Diffractaic acid exhibits thioredoxin reductase 1 inhibition in lung cancer A549 cells

    • Authors: Şükran Günaydın, Emine Karaca Sulukoğlu, Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2023
    • Citation: Journal of Applied Toxicology
    • DOI: 10.1002/jat.4505
  • Title: Effect of evernic acid on human breast cancer MCF‐7 and MDA‐MB‐453 cell lines via thioredoxin reductase 1: A molecular approach

    • Authors: Şeyda Nur Kalın, Ahmet Altay, Harun Budak
    • Year: 2023
    • Citation: Journal of Applied Toxicology
    • DOI: 10.1002/jat.4451
  • Title: In Vitro Cytotoxic Evaluation of a Silver(I) Complex Including Non-Steroidal Anti-Inflammatory Drug Niflumic Acid and 3-Picoline on Human-Derived Cancer Cell Lines

    • Authors: Sema Çağlar, Ahmet Altay, Bülent Çağlar, Esma Kübra Kağan Yeniçeri, Betül Harurluoğlu
    • Year: 2022
    • Citation: Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
    • DOI: 10.18185/erzifbed.1130634
  • Title: A Biochemical Approach for Hedysarum candidissimum from Turkey: Screening Phytochemicals, Evaluation of Biological Activities, and Molecular Docking Study

    • Authors: Ahmet Altay, Esma Yeniceri, Parham Taslimi, Tugba Taskin‐Tok, Mustafa Abdullah Yilmaz, Ekrem Koksal
    • Year: 2022
    • Citation: Chemistry & Biodiversity
    • DOI: 10.1002/cbdv.202200348
  • Title: Phytochemical Analysis and Biological Evaluation of Hypericum linarioides Bosse: in Vitro and in Silico Studies

    • Authors: Ahmet Altay, Esma Kübra Kağan Yeniçeri, Parham Taslimi, Tugba Taskin‐Tok, Mustafa Abdullah Yılmaz, Ekrem Köksal
    • Year: 2022
    • Citation: ChemistrySelect
    • DOI: 10.1002/slct.202200039